Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Pediatric MATCH: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes

Complete title: APEC1621H, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genes

Research Study Number APEC1621H
Principal Investigator Navin Pinto, MD
Phase II

Research Study Description

This phase II trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid (DNA) damage repair genes that have spread to other places in the body and have come back or do not respond to treatment. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "LOOK UP TRIAL AT NIH" link above. **

Other eligibility criteria may apply.

Research Study Number APEC1621H
Contact Navin Pinto, MD
Telephone 206/987-2106

Keywords: Central Nervous System (CNS); Glioma; Hematologic Malignancies; Histiocytosis; Lymphoma; Lymphoproliferative Disorders; Medulloblastoma; Pediatric Cancers, Miscellaneous; Neuroblastoma; Lymphoma, Non-Hodgkin (NHL); Neuroectodermal Tumors, Primitive (PNET); Sarcoma; Solid Tumors; Wilms' Tumor; Neoplasms, Germ Cell and Embryonal; Immunoproliferative Disorders; Neuroectodermal Tumors; Ependymoma; Rhabdomyosarcoma; Sarcoma, Ewing; Neoplasms, Neuroepithelial; Osteosarcoma; Neoplasms, Connective and Soft Tissue; Immune System Diseases; Rhabdoid Tumor; Nervous System Diseases; Histiocytosis, Langerhans-Cell; Hepatoblastoma; Neuroectodermal Tumors, Primitive, Peripheral

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials